A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Genentech, Inc.
National Cancer Institute (NCI)
Vividion Therapeutics, Inc.
Erasca, Inc.
Novartis
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Eli Lilly and Company
Pfizer
Dana-Farber Cancer Institute
Sutro Biopharma, Inc.
Pfizer
Tizona Therapeutics, Inc
Amgen
IDEAYA Biosciences
M.D. Anderson Cancer Center
Eli Lilly and Company
Novartis
Amgen
Sairopa B.V.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Tempest Therapeutics
Valo Therapeutics Oy
Epkin
Bicara Therapeutics
Xencor, Inc.
Incyte Corporation
Toray Industries, Inc
Trishula Therapeutics, Inc.
DEKA Biosciences
Boehringer Ingelheim
Turnstone Biologics, Corp.
Merck Sharp & Dohme LLC
Carisma Therapeutics Inc
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Eli Lilly and Company
Astellas Pharma Inc
NGM Biopharmaceuticals, Inc
Adlai Nortye Biopharma Co., Ltd.
Pliant Therapeutics, Inc.
NGM Biopharmaceuticals, Inc
Celldex Therapeutics
Ikena Oncology
Ikena Oncology
Wellmarker Bio
Stingthera, Inc.
Hefei TG ImmunoPharma Co., Ltd.
Atreca, Inc.
Corvus Pharmaceuticals, Inc.
Emory University